



Alzinova's CFO plans for retirement and the Company initiates a recruitment process for a successor

Alzinova AB (publ) announces today that Alzinova's CFO, Håkan Skogström, has announced his intention to retire. Skogström has been a part-time CFO at Alzinova since spring 2020 and will leave his position during next year. The company is now initiating a process to recruit a successor.

Alzinova's CFO Håkan Skogström has announced that he wishes to retire in 2024 and the Company has therefore initiated a process to recruit a full-time CFO as a replacement. Håkan Skogström will remain in the role as CFO until a new candidate is recruited to ensure a good handover.

CEO Kristina Torfgård comments:

"We want to thank Håkan for the time he has spent with us and for his excellent work for Alzinova. With his long experience, Håkan has been a great help in developing our organisation and contributed to enabling the next phase of the company. We are now starting the recruitment process to find Håkan's successor, and I am grateful that he will stay on until we have a replacement in place. We wish Håkan good luck after a long and successful career."

For more information, please contact:

Kristina Torfgård, CEO

Tel. +46 708 46 79 75

E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com



Attachments

Alzinova's CFO plans for retirement and the Company initiates a recruitment process for a successor